## Edgar Filing: IMMUNOMEDICS INC - Form 4

IMMUNOM Form 4	IEDICS INC									
August 25, 2									PROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287	
Check th if no long subject to Section 1 Form 4 o	IGES IN BENEFICIAL OWNERSHIP OF SECURITIES					Expires: Estimated a burden hour response	•			
Form 5 obligatio may cont <i>See</i> Instru 1(b).	ns Section 17(a	suant to Section 1 a) of the Public U 30(h) of the Ir	tility Hole	ding Cor	npan	y Act of	1935 or Section			
(Print or Type I	Responses)									
1. Name and A Stark Don C	er Name <b>and</b> Ticker or Trading NOMEDICS INC [IMMU]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
	(First) (N NOMEDICS, INC RICAN ROAD	(Month/I	f Earliest Tr Day/Year) 2016	ransaction			X Director Officer (give t below)	10%	) Owner r (specify	
			endment, Date Original nth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
MORRIS P	LAINS, NJ 0795(	)					Form filed by M Person			
(City)	(State)	(Zip) Tab	le I - Non-I	Derivative	Secur	rities Acqu	uired, Disposed of,	or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8) Code V	(Instr. 3,	spose	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	08/24/2016		S	9,900	D	2.9748 (1) (2)	55,848	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## Edgar Filing: IMMUNOMEDICS INC - Form 4

## **Reporting Owners**

Relationships						
Director	10% Owner	Officer	Other			
Х						
08/25/2016						
	Date					
	210000	Director 10% Owner X 08/25/2	Director 10% Owner Officer X 08/25/2016			

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The price in column 4 is a weighted average price. The prices actually received by the reporting person in this transaction range from \$2.9737 to \$2.9762.
- (2) The reporting person has provided to the issuer, and the issuer will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range reported.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.